Cellular Origins Collaborates with Immatics on Automation for Cell Therapy Manufacturing

Cellular Origins agreed to collaborate with Immatics in utilizing Cellular Origins’ automated mobile robotic platform, Constellation^®, within certain parts of the company’s manufacturing processes. The collaboration will explore how automation technologies can further contribute to more efficient and scalable manufacturing processes for next-generation cell therapies.

“Following the first cell therapy approvals in 2017, there has been widespread success in treating blood cancers, while progress in solid tumors has been more limited. Immatics is now working to advance clinically validated approaches that could expand treatment options for these,” said Edwin Stone, PhD, CEO, Cellular Origins. “Current manual manufacturing methods can limit the number of patients who are able to access approved therapies,” he added.

“Effective cell therapies for solid-tumor patients is one of the most exciting developments in our field but will need the manufacturing challenges to be addressed to deliver on its potential. Our partnership with Immatics aims to support the scalable and cost-effective manufacturing of their therapies so that more patients could potentially benefit.”

“Immatics has generated extensive data demonstrating the potential of precision targeting PRAME, a target expressed in more than 50 cancers,” noted Ali Mohamed, PhD, senior vice president of CMC, Immatics. “As we continue to advance our programs, it is important that we also develop manufacturing capabilities that can support future scale. We are pleased to collaborate with Cellular Origins to explore how the Constellation platform and our integrated manufacturing processes could support the scalable production of our therapies as we move toward potential approvals.”

The post Cellular Origins Collaborates with Immatics on Automation for Cell Therapy Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News.